Trial Profile
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 17 Apr 2024 Planned End Date changed from 30 Nov 2021 to 31 Dec 2024.
- 17 Apr 2024 Planned primary completion date changed from 30 Nov 2021 to 31 Dec 2024.
- 17 Apr 2024 Status changed from recruiting to active, no longer recruiting.